Dr. Smith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2200 Childrens Way
Nashville, TN 37232Phone+1 615-936-1762Fax+1 615-936-1767
Summary
- Dr. Brianna Smith is a pediatric hematologist/oncologist in Nashville, TN and is affiliated with Vanderbilt University Medical Center.
Education & Training
- Vanderbilt University Medical CenterFellowship, Pediatric Hematology/Oncology, 2017 - 2020
- Johns Hopkins All Children's HospitalResidency, Pediatrics, 2014 - 2017
- Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2014
Certifications & Licensure
- TN State Medical License 2021 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
- American Board of PediatricsBoard Certification General Pediatrics
- American Board of PediatricsBoard Certification Pediatric Hematology/Oncology
Clinical Trials
- Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Start of enrollment: 2021 Nov 15
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 5 citationsSelective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes.Melissa A Fischer, Yuanbin Song, Maria P Arrate, Rana Gbyli, Matthew T Villaume
Haematologica. 2023-02-01 - 5 citationsSecond Report of PDE10A-BRAF Fusion in Pediatric Spindle Cell Sarcoma With Infantile Fibrosarcoma-Like Morphology Suggesting PDE10A-BRAF Fusion Is a Recurrent Event:Caitlin Hughes, Hernan Correa, Daniel J. Benedetti, Brianna N Smith, Janos Sumegi
Pediatric and Developmental Pathology. 2021-06-13 - 22 citationsPevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.Dan Cojocari, Brianna N Smith, Julie J Purkal, Maria Pia Arrate, Jason Huska
Haematologica. 2021-04-15
Grant Support
- Turner Cockrell Discovery GrantTurner's Heroes Foundation2021–2023
- K12 Research Training GrantVanderbilt Clinical Oncology Research Scholars Program2020–2022
- T32 Research Training GrantVanderbilt Integrated Molecular Oncology Research Training Program2018–2020
Professional Memberships
- Member
- Member
- American Society of Pediatric Hematology and Oncology (ASPHO)Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: